#Belgium #Autoimmune Disease #AbolerIS Pharma #ABO21009 #Gosselies

AbolerIS Pharma's New Scientific Advisory Board

AbolerIS Pharma, a clinical-stage biopharmaceutical firm dedicated to enhancing the lives of individuals with autoimmune and inflammatory disorders, has recently revealed the establishment of its Scientific Advisory Board (SAB). This board consists of highly esteemed experts in the development of drugs for autoimmune and inflammatory diseases, who will collaborate closely with AbolerIS to propel their leading program, ABO21009, a humanized anti-CD45RC monoclonal antibody, through the initial Phase 1 trials focusing on rheumatoid arthritis (RA).

The objective behind forming the SAB is not just limited to advancing ABO21009 for RA. AbolerIS has larger ambitions; pending promising results from the clinical trials, the company plans to expand the research to encompass additional autoimmune diseases that remain challenging for many patients. Despite advancements in medical research, achieving a durable and long-lasting remission continues to be a struggle for numerous individuals suffering from conditions like RA, necessitating the expertise that the SAB brings to the table.

Expertise of the Advisory Board

The newly formed Scientific Advisory Board includes leading figures from renowned medical institutions who bring with them an extensive background in both clinical and preclinical research. Each member has been selected for their profound understanding of autoimmune diseases, which will be instrumental for the future of AbolerIS Pharma.

• - Dirk Elewaut, MD, PhD is the chairman of the SAB and a full professor at Ghent University Hospital in Belgium. His vast experience in immunology and inflammatory disease research positions him favorably to oversee the scientific direction of the SAB. He expressed his excitement about leading this distinguished group towards advancing groundbreaking therapies like ABO21009 to patients in desperate need of effective treatments.

• - Mary Crow, MD, PhD, renowned physician and researcher from New York, is another crucial member of the SAB. Her role at the Hospital for Special Surgery, along with her extensive research in lupus and autoimmune conditions, will provide vital insights into the potential applications of ABO21009 and beyond.

• - Other notable members include Georg Schett, MD, PhD from Germany, Rene Toes, PhD from the Netherlands, and Michel Goldman, MD, PhD, who has made significant contributions to immunology and pharmacotherapy.

• - Each member will aid in shaping the strategic research and development landscape of AbolerIS as it aims to diversify its therapeutic portfolio further, which may include other indications such as Sjögren's Disease, Graft-versus-Host Disease, Inflammatory Bowel Disease, and Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.

The Promise of ABO21009

ABO21009 itself is positioned as a revolutionary approach to treating autoimmune and inflammatory disorders, particularly RA. Its innovative multi-faceted mechanism works by selectively depleting CD45RC-positive cells, which perpetuate the autoimmune response. This targeted approach is designed to eliminate the harmful immune cells while leaving regulatory T-cells intact, allowing for a restoration of balance within the immune system. The anticipated outcome is a long-lasting remission in RA, promising a better quality of life for patients and reducing reliance on traditional therapeutic methods with extensive side effects.

Conclusion

AbolerIS Pharma is set to change the landscape of treatment for autoimmune diseases through its ambitious R&D efforts, spearheaded by both an experienced scientific advisory committee and a promising lead therapeutic program. The company's vision of making long-term remission achievable for patients in need is one that resonates deeply, as they continue to innovate in the field of immunotherapy. Learn more about their developments and future at AbolerIS Pharma.